Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidone

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 43, Issue , 2013, Pages 14-22

  de Souza, Daniela Fraga ^a   Wartchow, Krista ^a   Hansen, Fernanda ^a   Lunardi, Paula ^a   Guerra, Maria Cristina ^a   Nardin, Patrícia ^a   Gonçalves, Carlos Alberto ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Antipsychotics; Cytokines; Glia; S100B; Schizophrenia

Indexed keywords

GLUTATHIONE; HALOPERIDOL; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROTEIN S100B; RISPERIDONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; GLIA CELL; IMMUNOMODULATION; NEUROMODULATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TARGETING; RAT; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CELL LINE, TUMOR; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOMA; GLUTATHIONE; HALOPERIDOL; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; L-LACTATE DEHYDROGENASE; NERVE GROWTH FACTORS; NEUROGLIA; NITRIC OXIDE; OXIDATIVE STRESS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RISPERIDONE; S100 PROTEINS; TETRAZOLIUM SALTS; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871858574     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.12.001     Document Type: Article

References (59)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
2. Arnold S.E., Franz B.R., Trojanowski J.Q., Moberg P.J., Gur R.E. Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia. Acta Neuropathol 1996, 91:269-277.
3. Ashdown H., Dumont Y., Ng M., Poole S., Boksa P., Luheshi G.N. The role of cytokines in mediating effects of prenatal infection on the fetus: implications for schizophrenia. Mol Psychiatry 2006, 11:47-55.
4. Ashraf S., Bhattacharya K., Tian Y., Watterson K. Cytokine and S100B levels in paediatric patients undergoing corrective cardiac surgery with or without total circulatory arrest. Eur J Cardiothorac Surg 1999, 16:32-37.
5. Behrens M.M., Ali S.S., Dugan L.L. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci 2008, 28:13957-13966.
6. Blazquez Arroyo J.L., Fraile Malmierca E., Casadiego Cubides A., Llorca Ramon G., Ledesma Jimeno A. Glial reactivity after antipsychotic treatment. An experimental study in rats and its implications for psychiatry. Actas Esp Psiquiatr 2010, 38:278-284.
7. Browne R.W., Armstrong D. Reduced glutathione and glutathione disulfide. Methods Mol Biol 1998, 108:347-352.
8. Buyukuysal R.L. Protein S100B release from rat brain slices during and after ischemia: comparison with lactate dehydrogenase leakage. Neurochem Int 2005, 47:580-588.
9. Damadzic R., Bigelow L.B., Krimer L.S., Goldenson D.A., Saunders R.C., Kleinman J.E., et al. A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis. Brain Res Bull 2001, 55:611-618.
10. de Souza D.F., Leite M.C., Quincozes-Santos A., Nardin P., Tortorelli L.S., Rigo M.M., et al. S100B secretion is stimulated by IL-1beta in glial cultures and hippocampal slices of rats: likely involvement of MAPK pathway. J Neuroimmunol 2009, 206:52-57.
11. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001, 33:637-668.
12. Donato R., Sorci G., Riuzzi F., Arcuri C., Bianchi R., Brozzi F., et al. S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 2009, 1793:1008-1022.
13. Edwards M.M., Robinson S.R. TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease. J Neural Transm 2006, 113:1709-1715.
14. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009, 35:528-548.
15. Gaitanaki C., Konstantina S., Chrysa S., Beis I. Oxidative stress stimulates multiple MAPK signalling pathways and phosphorylation of the small HSP27 in the perfused amphibian heart. J Exp Biol 2003, 206:2759-2769.
16. Garate I., Garcia-Bueno B., Madrigal J.L., Bravo L., Berrocoso E., Caso J.R., et al. Origin and consequences of brain toll-like receptor 4 pathway stimulation in an experimental model of depression. J Neuroinflammation 2011, 8:151.
17. Goncalves D.S., Lenz G., Karl J., Goncalves C.A., Rodnight R. Extracellular S100B protein modulates ERK in astrocyte cultures. NeuroReport 2000, 11:807-809.
18. Goncalves C.A., Leite M.C., Nardin P. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 2008, 41:755-763.
19. Goncalves C.A., Leite M.C., Guerra M.C. Adipocytes as an important source of serum S100B and possible roles of this protein in adipose tissue. Cardiovasc Psychiatry Neurol 2010, 2010:790431.
20. Griffin W.S., Sheng J.G., Royston M.C., Gentleman S.M., McKenzie J.E., Graham D.I., et al. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol 1998, 8:65-72.
21. Guerra M.C., Tortorelli L.S., Galland F., Da Re C., Negri E., Engelke D.S., et al. Lipopolysaccharide modulates astrocytic S100B secretion: a study in cerebrospinal fluid and astrocyte cultures from rats. J Neuroinflammation 2011, 8:128.
22. Hu J., Castets F., Guevara J.L., Van Eldik L.J. S100 beta stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes. J Biol Chem 1996, 271:2543-2547.
23. Khansari N., Shakiba Y., Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Patents Inflamm Allergy Drug Discov 2009, 3:73-80.
24. Kuroki T., Nagao N., Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 2008, 172:199-212.
25. Lara D.R., Gama C.S., Belmonte-de-Abreu P., Portela L.V., Goncalves C.A., Fonseca M., et al. Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res 2001, 35:11-14.
26. Leite M.C., Galland F., Brolese G., Guerra M.C., Bortolotto J.W., Freitas R., et al. A simple, sensitive and widely applicable ELISA for S100B: methodological features of the measurement of this glial protein. J Neurosci Methods 2008, 169:93-99.
27. Liu J., Shi Y., Tang J., Guo T., Li X., Yang Y., et al. SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochem Biophys Res Commun 2005, 328:335-341.
28. Mansur R.B., Zugman A., Asevedo Ede M., da Cunha G.R., Bressan R.A., Brietzke E. Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages. Psychiatry Clin Neurosci 2012, 66:247-260.
29. Marchi N., Cavaglia M., Fazio V., Bhudia S., Hallene K., Janigro D. Peripheral markers of blood-brain barrier damage. Clin Chim Acta 2004, 342:1-12.
30. Martinez-Cengotitabengoa M., Mac-Dowell K.S., Leza J.C., Mico J.A., Fernandez M., Echevarria E., et al. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res 2012, 137:66-72.
31. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70:663-671.
32. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009, 63:257-265.
33. Nardin P., Tramontina A.C., Quincozes-Santos A., Tortorelli L.S., Lunardi P., Klein P.R., et al. In vitro S100B secretion is reduced by apomorphine: effects of antipsychotics and antioxidants. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1291-1296.
34. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 1977, 83:346-356.
35. Pillai A., Parikh V., Terry A.V., Mahadik S.P. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2007, 41:372-386.
36. Pleines U.E., Morganti-Kossmann M.C., Rancan M., Joller H., Trentz O., Kossmann T. S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma 2001, 18:491-498.
37. Ponath G., Schettler C., Kaestner F., Voigt B., Wentker D., Arolt V., et al. Autocrine S100B effects on astrocytes are mediated via RAGE. J Neuroimmunol 2007, 184:214-222.
38. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008, 63:801-808.
39. Quincozes-Santos A., Abib R.T., Leite M.C., Bobermin D., Bambini-Junior V., Goncalves C.A., et al. Effect of the atypical neuroleptic risperidone on morphology and S100B secretion in C6 astroglial lineage cells. Mol Cell Biochem 2008, 314:59-63.
40. Quincozes-Santos A., Bobermin L.D., Tonial R.P., Bambini-Junior V., Riesgo R., Gottfried C. Effects of atypical (risperidone) and typical (haloperidol) antipsychotic agents on astroglial functions. Eur Arch Psychiatry Clin Neurosci 2010, 260:475-481.
41. Rothermundt M., Falkai P., Ponath G., Abel S., Burkle H., Diedrich M., et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 2004, 9:897-899.
42. Schmitt K.R., Kern C., Lange P.E., Berger F., Abdul-Khaliq H., Hendrix S. S100B modulates IL-6 release and cytotoxicity from hypothermic brain cells and inhibits hypothermia-induced axonal outgrowth. Neurosci Res 2007, 59:68-73.
43. Schroeter M.L., Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009, 14:235-237.
44. Shintani F., Kanba S., Maruo N., Nakaki T., Nibuya M., Suzuki E., et al. Serum interleukin-6 in schizophrenic patients. Life Sci 1991, 49:661-664.
45. Smith C., Toohey N., Knight J.A., Klein M.T., Teitler M. Risperidone-induced inactivation and clozapine-induced reactivation of rat cortical astrocyte 5-hydroxytryptamine (7) receptors: evidence for in situ G protein-coupled receptor homodimer protomer cross-talk. Mol Pharmacol 2011, 79:318-325.
46. Steiner J., Bielau H., Bernstein H.G., Bogerts B., Wunderlich M.T. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 2006, 77:1284-1287.
47. Steiner J., Bernstein H.G., Bogerts B., Gos T., Richter-Landsberg C., Wunderlich M.T., et al. S100B is expressed in, and released from, OLN-93 oligodendrocytes: influence of serum and glucose deprivation. Neuroscience 2008, 154:496-503.
48. Steiner J., Walter M., Wunderlich M.T., Bernstein H.G., Panteli B., Brauner M., et al. A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol Psychiatry 2009, 65:1107-1110.
49. Steiner J., Myint A.M., Schiltz K., Westphal S., Bernstein H.G., Walter M., et al. S100B serum levels in schizophrenia are presumably related to visceral obesity and insulin resistance. Cardiovasc Psychiatry Neurol 2010, 2010:480707.
50. Steiner J., Schroeter M.L., Schiltz K., Bernstein H.G., Muller U.J., Richter-Landsberg C., et al. Haloperidol and clozapine decrease S100B release from glial cells. Neuroscience 2010, 167:1025-1031.
51. Takanaga H., Yoshitake T., Hara S., Yamasaki C., Kunimoto M. cAMP-induced astrocytic differentiation of C6 glioma cells is mediated by autocrine interleukin-6. J Biol Chem 2004, 279:15441-15447.
52. Tansey M.G. Inflammation in neuropsychiatric disease. Neurobiol Dis 2010, 37:491-492.
53. Tchivileva I.E., Nackley A.G., Qian L., Wentworth S., Conrad M., Diatchenko L.B. Characterization of NF-kB-mediated inhibition of catechol-O-methyltransferase. Mol Pain 2009, 5:13.
54. Torgerson T.R., Colosia A.D., Donahue J.P., Lin Y.Z., Hawiger J. Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. J Immunol 1998, 161:6084-6092.
55. Tramontina F., Leite M.C., Goncalves D., Tramontina A.C., Souza D.F., Frizzo J.K., et al. High glutamate decreases S100B secretion by a mechanism dependent on the glutamate transporter. Neurochem Res 2006, 31:815-820.
56. Tramontina A.C., Tramontina F., Bobermin L.D., Zanotto C., Souza D.F., Leite M.C., et al. Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1580-1583.
57. Watanabe Y., Someya T., Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci 2010, 64:217-230.
58. Wee Yong V. Inflammation in neurological disorders: a help or a hindrance. Neuroscientist 2010, 16:408-420.
59. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Cao L.Y., Shen Y.C. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002, 57:247-258.